News & Updates
Filter by Specialty:
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.
Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer
08 Jan 2023
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.
Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?
05 Jan 2023
Assisted reproductive technology poses no excess risk of multiple sclerosis
Exposure to assisted reproductive technology (ART) does not appear to promote the development of multiple sclerosis, a study has found.
Assisted reproductive technology poses no excess risk of multiple sclerosis
01 Jan 2023
Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.
